UPADACITINIB (RINVOQ) prior authorization at Premera Blue Cross
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
Premera Blue Cross reviews UPADACITINIB (RINVOQ) prior authorizations against its medical policy for Janus Kinase Inhibitor [EPC]. The FDA-approved indication (2024) is SOLUTION. Premera Blue Cross-specific context: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Janus Kinase Inhibitor [EPC]
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Premera Blue Cross's medical policy URL referenced in the cover letter
Premera Blue Cross's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- WA-specific mental health parity violations
- Step therapy via Express Scripts
- Out-of-network reductions
- Specialty drug prior auth
If the PA is denied
Premera Blue Cross gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.premera.com/wa/provider) with the same packet plus a peer-reviewed citation supporting UPADACITINIB (RINVOQ)for the patient's indication.
Contact Premera Blue Cross
- Provider portal: https://www.premera.com/wa/provider
Frequently asked questions
What documentation does Premera Blue Cross need for UPADACITINIB (RINVOQ) prior auth?
Premera Blue Cross's typical PA packet for UPADACITINIB (RINVOQ): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Janus Kinase Inhibitor [EPC], expect clinical-criteria documentation specific to this class.
What's the turnaround time at Premera Blue Cross?
Standard UPADACITINIB (RINVOQ) PA decisions at Premera Blue Cross: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Premera Blue Cross most often reject UPADACITINIB (RINVOQ) for?
Across Premera Blue Cross's book the common rejection patterns include: WA-specific mental health parity violations; Step therapy via Express Scripts; Out-of-network reductions. For UPADACITINIB (RINVOQ) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Premera Blue Cross on UPADACITINIB (RINVOQ)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the UPADACITINIB (RINVOQ) PA packet
Open ApprovalHelp — generate a UPADACITINIB (RINVOQ) prior-auth packet tailored to Premera Blue Cross's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com